Baseline splenic volume as a surrogate marker of FOLFIRINOX efficacy in advanced pancreatic carcinoma

BACKGROUND: The FOLFIRINOX regimen is the standard first-line treatment for advanced pancreatic adenocarcinoma (aPDAC). However, because of its potential toxicity, predictive biomarkers could help clinical decision-making. METHODS: A cohort of 97 aPDAC patients treated with first-line FOLFIRINOX wer...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncotarget
Hlavní autoři: Aarnink, Anne, Richard, Corentin, Truntzer, Caroline, Vincent, Julie, Bengrine, Leila, Vienot, Angélique, Borg, Christophe, Ghiringhelli, Francois
Médium: Artigo
Jazyk:Inglês
Vydáno: Impact Journals LLC 2018
Témata:
Research Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5986639/
https://ncbi.nlm.nih.gov/pubmed/29876012
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25424
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky